Related Experiment Videos

Ankyrin Repeat Domain 1: A Key Regulatory Factor and Emerging Therapeutic Target in Heart Disease

Ziyuan Wang1, Qiong Du2, Shizhong Zhang1

  • 1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, 443002 Yichang, Hubei, China.

Reviews in Cardiovascular Medicine
|July 31, 2026
PubMed

Insights

Ankyrin repeat domain 1 (ANKRD1) plays a crucial role in cardiovascular diseases (CVD). Understanding its function offers new therapeutic strategies for heart conditions.

Area of Science:

  • Cardiovascular research
  • Molecular biology
  • Genetics

Background:

  • Cardiovascular disease (CVD) is a leading global cause of death.
  • Ankyrin repeat domain 1 (ANKRD1), also known as cardiac ankyrin repeat protein (CARP), is implicated in CVD.
  • ANKRD1's nucleocytoplasmic shuttling and multi-domain mechanism are key to its role in cardiovascular pathology.

Purpose of the Study:

  • To review the molecular structure and function of ANKRD1.
  • To elucidate ANKRD1's role in cardiovascular diseases like myocardial remodeling, cardiomyopathy, and heart failure.
  • To evaluate ANKRD1 as a potential therapeutic target for CVD.

Main Methods:

  • Literature review of ANKRD1's structure and function.
  • Analysis of ANKRD1's involvement in cardiovascular pathological processes.
  • Evaluation of ANKRD1 as a therapeutic target.

Main Results:

  • ANKRD1 exhibits significant roles in myocardial remodeling, cardiomyopathy, cardiac development, myocardial infarction, and heart failure.
  • The molecular structure and nucleocytoplasmic shuttling of ANKRD1 are critical to its function.
  • ANKRD1 presents a promising target for novel CVD therapies.

Conclusions:

  • ANKRD1 is a key player in the pathogenesis and progression of cardiovascular diseases.
  • Targeting ANKRD1 may offer new avenues for precision diagnosis and treatment of CVD.
  • Further research into ANKRD1 mechanisms can advance cardiovascular medicine.

Keywords:
ankyrin repeat domain 1cardiac remodelingcardiomyopathycardiovascular diseaseheart failuremyocardial infarction

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...